Modification of lipoprotein metabolism and function driving atherogenesis in diabetes

被引:11
|
作者
Luciani, Lorenzo [1 ,2 ,3 ]
Pedrelli, Matteo [1 ,2 ,4 ]
Parini, Paolo [1 ,2 ,4 ]
机构
[1] Karolinska Inst, Dept Lab Med, Cardio Metab Unit, Stockholm, Sweden
[2] Karolinska Inst, Dept Med Huddinge, Stockholm, Sweden
[3] St Anna Sch Adv Studies, Interdisciplinary Ctr Hlth Sci, Pisa, Italy
[4] Karolinska Univ Hosp, Med Unit Endocrinol Theme Inflammat & Ageing, Stockholm, Sweden
关键词
Lipoproteins; Apolipoproteins; Atherogenesis; Diabetes; Cardiometabolic disease; Human; Pre -clinical studies; Cholesterol; Triglycerides; LOW-DENSITY-LIPOPROTEIN; TRIGLYCERIDE-RICH LIPOPROTEINS; DE-NOVO LIPOGENESIS; PLASMINOGEN-ACTIVATOR INHIBITOR-1; VASCULAR ENDOTHELIAL-CELLS; PROTEOGLYCAN-BINDING-SITE; B-CONTAINING LIPOPROTEINS; GLYCATED LDL INCREASES; CORONARY-HEART-DISEASE; APOLIPOPROTEIN C-III;
D O I
10.1016/j.atherosclerosis.2024.117545
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease, characterized by raised blood glucose levels and impaired lipid metabolism resulting from insulin resistance and relative insulin deficiency. In diabetes, the peculiar plasma lipoprotein phenotype, consisting in higher levels of apolipoprotein B-containing lipoproteins, hypertriglyceridemia, low levels of HDL cholesterol, elevated number of small, dense LDL, and increased nonHDL cholesterol, results from an increased synthesis and impaired clearance of triglyceride rich lipoproteins. This condition accelerates the development of the atherosclerotic cardiovascular disease (ASCVD), the most common cause of death in T2DM patients. Here, we review the alteration of structure, functions, and distribution of circulating lipoproteins and the pathophysiological mechanisms that induce these modifications in T2DM. The review analyzes the influence of diabetes-associated metabolic imbalances throughout the entire process of the atherosclerotic plaque formation, from lipoprotein synthesis to potential plaque destabilization. Addressing the different pathophysiological mechanisms, we suggest improved approaches for assessing the risk of adverse cardiovascular events and clinical strategies to reduce cardiovascular risk in T2DM and cardiometabolic diseases.
引用
收藏
页数:13
相关论文
共 50 条